{"id":2245,"date":"2017-08-03T18:00:01","date_gmt":"2017-08-03T12:30:01","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2245"},"modified":"2021-07-24T12:56:48","modified_gmt":"2021-07-24T07:26:48","slug":"the-business-cocktail-31","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-31","title":{"rendered":"Allergan sell; AZ, Merck team up; Roche\u2019s MS drug; Chinese API maker receives a warning letter"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69fa83e94f2c4\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69fa83e94f2c4\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-31\/#Allergan_can_finally_sell_its_losing_stake_in_Teva_Will_it\" >Allergan can finally sell its losing stake in Teva. Will it?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-31\/#AstraZeneca_Merck_team_up_on_Lynparza_combos_in_collaboration_worth_up_to_85B\" >AstraZeneca, Merck team up on Lynparza combos in collaboration worth up to $8.5B<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-31\/#Roches_deep_discount_for_MS_drug_Ocrevus_pays_off_big_for_Swiss_drug_maker\" >Roche\u2019s deep discount for MS drug Ocrevus pays off big for Swiss drug maker<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-31\/#Chinese_API_maker_receives_a_warning_letter_from_French_regulatory_agency_and_a_recall\" >Chinese API maker receives a warning letter from French regulatory agency, and a recall<\/a><\/li><\/ul><\/nav><\/div>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Allergan_can_finally_sell_its_losing_stake_in_Teva_Will_it\"><\/span>Allergan can finally sell its losing stake in Teva. Will it?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Allergan, which acquired a 9.9% stake in the Israeli drugmaker last year as part of the pair\u2019s $40 billion-plus generics deal, currently stands as Teva\u2019s largest shareholder. Those shares, worth $5.3 billion when Allergan acquired them, have been locked down for the last year, with Allergan unable to sell them, Israeli newspaper Globes reports. And in that time, they\u2019ve dropped more than $2 billion in value to $3.2 billion. As of Wednesday, though, Allergan\u2014which has said it wasn\u2019t a \u201clong-term holder\u201d of Teva\u2019s stock\u2014can do as it pleases. So far, it hasn\u2019t said whether it plans to dump the stake this year, with CFO Maria Teresa Hilado telling shareholders on February\u2019s fourth-quarter 2016 earnings call that \u201cin August we will evaluate whether we would sell.\u201d If it does, though, Teva could be in for even more pain than it\u2019s already faced in the two years since it said it\u2019d be snapping up Allergan\u2019s generics unit, Actavis. Between then and now, shares have plunged 55% as skepticism over that deal, a botched buy of Mexico\u2019s Rimsa, badly missed sales forecasts, a slew of exec exits and more took their toll. The result? Teva\u2019s market cap currently sits at around $31.49 billion, less than the company paid for Actavis in the first place.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"AstraZeneca_Merck_team_up_on_Lynparza_combos_in_collaboration_worth_up_to_85B\"><\/span>AstraZeneca, Merck team up on Lynparza combos in collaboration worth up to $8.5B<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Cancer drug Lynparza has been one of AstraZeneca\u2019s biggest hopes amid generic competition for its blockbuster statin Crestor and spotty results for its pipeline. But now, Merck &amp; Co. has snapped up half the rights to Lynparza in an $8.5 billion deal, $1.6 billion up front and the rest contingent on sales and regulatory milestones, plus potential licensing payments worth up to $750 million. It\u2019s an ongoing partnership that includes co-development of the medication with AstraZeneca\u2019s checkpoint inhibitor Imfinzi, a fourth-to-market therapy which just fell short in a lung cancer combo trial, and Merck\u2019s Keytruda, which is among the top drugs in the same class. AstraZeneca\u2019s pipeline drug selumetinib, a MEK inhibitor, and related combinations also come along. AstraZeneca billed the partnership as a way to extend Lynparza\u2019s reach by racking up new indications and developing combo cocktails. Keytruda, after all, zoomed to blockbuster status, and combining that PD-1 drug with the AstraZeneca PARP inhibitor could hitch Lynparza to those coattails.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Roches_deep_discount_for_MS_drug_Ocrevus_pays_off_big_for_Swiss_drug_maker\"><\/span>Roche\u2019s deep discount for MS drug Ocrevus pays off big for Swiss drug maker<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Roche caught the market by surprise when it priced its highly touted new multiple sclerosis drug Ocrevus at a 25% discount to the competition. Roche\u2019s gambit has surprised again, with Ocrevus winning immediate uptake and generating $200 million in its first quarter on the market. The drug appears to have outperformed Roche\u2019s estimates because the drug maker today said it has decided to raise its 2017 forecast. It wasn\u2019t Ocrevus alone that prompted Roche to up its guidance. Newer cancer drugs Tecentriq and Perjeta also performed well, with Perjeta sales up 17% to CHF 1.1 billion in the first half (PDF)\u00a0 of the year and Tecentriq adding CHF 237 million, up 19%. Pharmaceuticals sales for H1 were up 5% to CHF 20.5 billion. Ocrevus, approved in March, came to the market with all of the elements that would have allowed Roche to price it at a premium to other drugs in the market.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Chinese_API_maker_receives_a_warning_letter_from_French_regulatory_agency_and_a_recall\"><\/span>Chinese API maker receives a warning letter from French regulatory agency, and a recall<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">French drug regulators slapped Chinese API maker Chongqing Succeway Pharmaceutical with a warning letter and issued a recall following an inspection last month. In the notice posted on the European Medicines Agency GMP website, the French National Agency for Medicines and Health Products said inspectors found a total of 22 issues with the facility located in Chongqing, China. The latest inspection was on June 24. Of the total issues, one was classified as critical and three as major. The problems included manipulation, backdating and falsification of documents such as batch manufacturing record, report of starting material manufacturer audit, GC and HPLC chromatograms. The major issue was an undeclared workshop \u201cwithout any traceability of the activities undertaken\u201d while the two major issues included undeclared storage of unidentified product and poor standards for maintaining batch manufacturing records. The agency called for a recall of all batches of rilmenidine dihydrogen phosphate, which is used in making drugs to treat hypertension.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Allergan can finally sell its losing stake in Teva. Will it? Allergan, which acquired a 9.9% stake in the Israeli drugmaker last year as part of the pair\u2019s $40 billion-plus generics deal, currently stands as Teva\u2019s largest shareholder. Those shares, worth $5.3 billion when Allergan acquired them, have been locked down for the last year, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2122,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[975,96,976,971,970,972,395,973,524,974],"industry":[17225],"therapeutic_areas":[17227,17228],"class_list":["post-2245","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-allergen","tag-astrazeneca","tag-buyout","tag-chinese-api","tag-french-regulatory-agency","tag-kisqali","tag-merck","tag-ocrevus","tag-roche","tag-tava","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Allergan sell; AZ, Merck team up; Roche\u2019s MS drug; API maker receives<\/title>\n<meta name=\"description\" content=\"Allergan, which acquired a 9.9% stake in the Israeli drugmaker last year as part of the pair\u2019s $40 billion-plus generics deal, currently stands...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-31\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Allergan sell; AZ, Merck team up; Roche\u2019s MS drug; API maker receives\" \/>\n<meta property=\"og:description\" content=\"Allergan, which acquired a 9.9% stake in the Israeli drugmaker last year as part of the pair\u2019s $40 billion-plus generics deal, currently stands...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-31\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-08-03T12:30:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09021257\/ma.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"3000\" \/>\n\t<meta property=\"og:image:height\" content=\"2250\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Allergan sell; AZ, Merck team up; Roche\u2019s MS drug; API maker receives","description":"Allergan, which acquired a 9.9% stake in the Israeli drugmaker last year as part of the pair\u2019s $40 billion-plus generics deal, currently stands...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-31","og_locale":"en_US","og_type":"article","og_title":"Allergan sell; AZ, Merck team up; Roche\u2019s MS drug; API maker receives","og_description":"Allergan, which acquired a 9.9% stake in the Israeli drugmaker last year as part of the pair\u2019s $40 billion-plus generics deal, currently stands...","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-31","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-08-03T12:30:01+00:00","article_modified_time":"2021-07-24T07:26:48+00:00","og_image":[{"width":3000,"height":2250,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09021257\/ma.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-31","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-31","name":"Allergan sell; AZ, Merck team up; Roche\u2019s MS drug; API maker receives","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-31#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-31#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09021257\/ma.jpg","datePublished":"2017-08-03T12:30:01+00:00","dateModified":"2021-07-24T07:26:48+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Allergan, which acquired a 9.9% stake in the Israeli drugmaker last year as part of the pair\u2019s $40 billion-plus generics deal, currently stands...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-31"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-31#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09021257\/ma.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09021257\/ma.jpg","width":"3000","height":"2250","caption":"Personalized Medicine"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09021257\/ma-300x225.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Allergen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Buyout<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Chinese API<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">French Regulatory Agency<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Kisqali<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Merck<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ocrevus<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Roche<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Tava<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Allergen<\/span>","<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">Buyout<\/span>","<span class=\"advgb-post-tax-term\">Chinese API<\/span>","<span class=\"advgb-post-tax-term\">French Regulatory Agency<\/span>","<span class=\"advgb-post-tax-term\">Kisqali<\/span>","<span class=\"advgb-post-tax-term\">Merck<\/span>","<span class=\"advgb-post-tax-term\">Ocrevus<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>","<span class=\"advgb-post-tax-term\">Tava<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Aug 3, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Aug 3, 2017 6:00 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2245","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2245"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2245\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2122"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2245"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2245"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2245"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2245"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2245"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}